Herpesviridae Infections clinical trials
The registry lists 31 studies for Herpesviridae Infections across 8 countries. 4 are recruiting or about to start. 6 of them are mainly about Herpesviridae Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-07-22. Counting its 14 narrower conditions too, such as Burkitt Lymphoma: 2,471 studies, 417 open.
Get an email when these change. Save the Herpesviridae Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Center for Research Resources (NCRR) (7) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Shenzhen Shenxin Biotechnology Co., Ltd (2) · Lower Saxony Center for Nephrology (1) · Jiangsu Province Centers for Disease Control and Prevention (1) · Liverpool School of Tropical Medicine (1) · University of Fujairah (1) · National Heart, Lung, and Blood Institute (NHLBI) (1)
What is being tested here
Drugs under test in Herpesviridae Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Acyclovir | 0 | 3 | 7 |
| Ganciclovir | 0 | 1 | 2 |
| Zidovudine | 0 | 0 | 1 |
| Trifluridine | 0 | 0 | 1 |
| Valacyclovir | 0 | 0 | 1 |
| Sevirumab | 0 | 0 | 1 |
| Morphine | 0 | 1 | 1 |
| Nortriptyline | 0 | 1 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Nov 2027Improving Prescribing Quality for Oral Mucosal Disorders Using a Pharmacist-Led Model · University of Fujairah
Who these studies take
Of the 2 Herpesviridae Infections studies recruiting now, 1 (50%) set no upper age limit and 1 (50%) stop at 75 or younger. 1 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (50%) | 1 (50%) |
| 18 | 1 (50%) | 1 (50%) |
| 30 | 0 (0%) | 0 (0%) |
| 40 | 1 (50%) | 1 (50%) |
| 50 | 1 (50%) | 1 (50%) |
| 65 | 1 (50%) | 1 (50%) |
| 75 | 1 (50%) | 1 (50%) |
| 85 | 1 (50%) | 1 (50%) |
Across all 31 studies, recruiting or not: 48% stop at 75 or younger and 39% at 65; 55% take children; 3% are for women only and 3% for men only; 26% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 31 of 31. search them.
- Improving Prescribing Quality for Oral Mucosal Disorders Using a Pharmacist-Led ModelNot yet recruitingNCT07721090Not applicable
- Long-term Effectiveness of the Live Attenuated Herpes Zoster VaccineRecruitingNCT075853701 country
- A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy ParticipantsNot yet recruitingNCT07205796Phase 2
- Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric PatientsRecruitingNCT051985701 country
- A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy ParticipantsCompletedNCT06375512Phase 12 countries
- Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCTCompletedNCT044128111 country
- Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric BurnsCompletedNCT06380647Not applicable1 country
- ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)CompletedNCT01600079
- A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3CompletedNCT00000712Phase 21 country
- Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical TrifluridineCompletedNCT00000635Not applicable1 country
- Cups or Cash for Girls Trial to Reduce Sexual and Reproductive Harm and School DropoutCompletedNCT03051789Not applicable1 country
- An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes LabialisStatus unknownNCT03977792Phase 2
- Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy AdultsCompletedNCT02826798Phase 11 country
- Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care UnitWithdrawnNCT00844155Not applicable1 country
- Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and AdolescentsCompletedNCT02250274Phase 41 country
- VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.CompletedNCT00116844Phase 41 country
- Assessment of Patients With Multiple Sclerosis (MS)CompletedNCT000011561 country
- Herpesvirus in Idiopathic Pulmonary FibrosisCompletedNCT002286701 country
- Inflammation, Infection, and Future Cardiovascular RiskCompletedNCT00005496
- Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in ChinaCompletedNCT01459081Phase 31 country
- The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAUCompletedNCT00000654Phase 21 country
- The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With PeriodantitisStatus unknownNCT012485981 country
- Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United StatesCompletedNCT000267281 country
- Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft RecipientsCompletedNCT00373165Phase 4
- Phase I/II Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus InfectionCompletedNCT00004644Phase 1/2
- Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to the Skin, Eyes, and MouthCompletedNCT00004757Phase 3
- Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and MouthCompletedNCT00006135Phase 32 countries
- Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System DiseaseCompletedNCT00004642Phase 1/2
- Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic NeuralgiaCompletedNCT00004390Phase 3
- Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus InfectionCompletedNCT00004278Phase 3
- Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous SystemStatus unknownNCT00006132Phase 32 countries